bone marrow blasts, 2 with splenomegaly, 7 with diploid cytogenetics and 1 with JAK2-V617F mutation. Whether these patients share a specific genetic phenotype is conceivable, and molecular characterization of this subgroup is ongoing.
) and other tyrosine kinase inhibitors (TKIs) have been shown to be transported by the ATP-binding cassette (ABC) drug transporters P-glycoprotein (P-gp) and ABCG2. 1, 2 This is clinically important as the transporters not only hamper the bioavailability of these TKIs but may also cause the emergence of drug resistance in patients. We have previously shown that imatinib and nilotinib interact at the substrate-binding pocket of ABC transporters, but do not interact at the adenosine triphosphate (ATP) Accepted article preview online 14 January 2014; advance online publication, 7 February 2014 Letters to the Editor sites of these transporters. 3 Identification of the key structural features of nilotinib and similar TKIs is essential for understanding their interaction with P-gp. Toward this goal, molecular docking, mutational mapping and quantitative structure-activity relationship (SAR) were used to identify nilotinib's binding site on P-gp.
Nilotinib was docked in a human P-gp homology model that was developed on the basis of the mouse P-gp crystal structure 4 using the XP-Glide docking method to understand the orientation and the complementarity of pharmacophore features of nilotinib with respect to the residues in the drug-binding pocket of P-gp ( Figure 1a) . Comparison of binding energy data for the docked poses of nilotinib at sites 1-4 (ref. 5) suggested site-1 (QZ59-RRR site) 4, 6 as the most favorable site (binding energy score of À 9.52 kcal/mol). The binding pocket is lined by residues that form electrostatic and hydrophobic contacts with a pyridine, a pyrimidine, a methyl-substituted phenyl ring, the carbonyl oxygen atom of the amide linker and the trifluoromethylphenyl ring of nilotinib (Figure 1a ). Among these, the Y307 residue showed significant interaction through hydrogen bonding to the pyridine ring (-N-HO-Y307, 2.4 Å), whereas A985 had hydrophobic contact with the CF 3 group (3.3 Å), phenyl ring (3.2 Å) and imidazole ring (4.1 Å) of nilotinib. Furthermore, M949 also showed hydrophobic contact with the imidazole ring (5.1 Å) of nilotinib (highlighted in red in Figure 1a) . Therefore, the residues (Y307, M949 and A985) that interact with three major functional groups (pyridine, CF 3 and imidazole) of nilotinib were selected for further analysis. The docking studies indicated these residues might determine the orientation and stabilization of nilotinib within the substrate-binding site of P-gp. These residues were mutated to Cys residue in a Cys-less P-gp to verify their role in interaction with nilotinib. Control Cys-less wild-type (WT) P-gp, Y307C, M949C and A985C P-gp mutants were expressed in HeLa cells (Supplementary Figure S2 ; mutants exhibited similar expression and transport of fluorescent substrates as Cys-less WT P-gp) and High-Five insect cells, as described in Supplementary Materials and Methods. Crude membranes from High-Five insect cells expressing similar levels of mutant proteins ( Figure 1b) were used to determine the interaction of these mutant P-gps with nilotinib. The effect of nilotinib was evaluated on ATPase activity and on photolabeling of mutant P-gps with [
125 I]-IAAP binding (Figure 1c  and Supplementary Table S1 ), as these approaches can be used to determine the interaction of substrates at the substrate-binding pocket of P-gp. 7, 8 Nilotinib's ability to stimulate the ATPase activity of Y307C-, M949C-and A985C-mutant P-gps was significantly reduced or abolished compared with Cys-less WT P-gp (Supplementary Table S1 ). Similarly, nilotinib's ability to compete for [
125 I]-IAAP photolabeling was significantly reduced for Y307C-and almost completely lost for M949C-and A985C-mutant P-gps (Figure 1c and Supplementary Table S1 ). These observations provided experimental support to the in silico docking studies. The residues Y307, M949 and A985 contribute to nilotinib binding, indicating that site-1 may be the primary binding site for nilotinib on P-gp. In silico introduction of these mutations in the homology model helped to visualize the local changes in the binding pocket (Supplementary Figure S3) . In the nilotinib-docked model of P-gp, pyridine nitrogen was present at a position 2.4 Å from the side chains of Y307; M949 was 5.1 Å from the imidazole ring, while A985 was 4.1 Å from the imidazole ring of nilotinib (Figure 1 ). In the triple mutant, the pyridine nitrogen atom lost one critical hydrogen bonding interaction with the Y307 residue, increasing the distance to 5.9 Å (Supplementary Figure S3) . Similarly, the hydrophobic interactions with the imidazole ring and the trifluoromethyl aniline moiety were lost when M949 and A985 were mutated to a hydrophilic cysteine residue (Supplementary Figure S3) . These data, taken together, provide clear evidence that site-1 is indeed the primary site of nilotinib binding on P-gp, with Y307 interacting with the pyridine ring, A985 interacting with the trifluoromethylphenyl group and M949 interacting with the imidazole ring of nilotinib.
To further validate the importance of functional groups of nilotinib for interacting with P-gp, five structural derivatives of nilotinib (Figure 2a ) that lacked critical functional groups such as the pyridine ring, pyrimidine ring, CF 3 group and imidazole ring were synthesized (as described in Supplementary Materials and Methods). These derivatives were evaluated for their interaction with P-gp by testing their ability to inhibit rhodamine 123 efflux from HeLa cells. Compound 1 (CF 3 replaced by CH 3 ) showed inhibition similar to that of nilotinib (data not shown), suggesting that substitution of fluorine with hydrogen at the CF 3 group is not a critical determinant of nilotinib's binding to the P-gp. Derivative 2 (no pyrimidine-pyridine ring system) was comparable to 3 (no pyridine ring), and 4 (imidazole replaced with a benzoic acid) was comparable to 5 (no imidazole ring) with respect to their ability to inhibit P-gp transport activity (data not shown). Therefore, 5 and 3, derivatives lacking the key imidazole or pyridine/pyrimidine rings, respectively, were further tested for interaction with P-gp. Compared with nilotinib, 3 completely lost the ability to inhibit photolabeling of P-gp with [ Table S2 ). Similarly, 3 did not stimulate the ATPase activity but 5 was equally effective as nilotinib in stimulating the ATPase activity of Cys-less WT P-gp (Supplementary Table S3 ). In addition, 5 partially inhibited the rhodamine 123 efflux by P-gp, whereas 3 had no effect (Figure 2c ). These results show that the interaction of nilotinib at the substrate-binding pocket of P-gp is significantly affected when the pyridine and/or pyrimidine ring is absent, whereas loss of the imidazole rings only slightly perturbs this interaction. Taken together, the results with derivatives corroborate the docking conformation and the mutational mapping data. Whereas the pyridine and pyrimidine moieties of nilotinib are important for interaction at the drug-binding pocket, the imidazole group is not critical for this interaction.
Nilotinib and imatinib were also compared for their binding orientation in the substrate-binding pocket of P-gp (Supplementary Figure S4) . As described in Supplementary Results, the observed affinity differences between nilotinib and imatinib for P-gp can be explained on the basis of the above docking analysis and its comparison with the known crystal structures of imatinib and nilotinib bound to BCR-ABL kinase. 9, 10 Several studies have used a docking-based approach to identify the substrate-binding pocket in P-gp, but most of those studies relied on either SAR or mutagenesis alone (reviewed in Palmeira et al. 11 ). We used a two-pronged approach, where the docked orientation of nilotinib was not only validated by directed mutagenesis of selected residues but also was verified using the structural derivatives of nilotinib. Although the data derived from modeling and mutational studies with nilotinib and its derivatives corroborate well with the docked conformation of nilotinib, there is still a possibility that nilotinib may bind to a secondary site because of the chemical and structural flexibility of a large drugbinding pocket that can accommodate more than one ligand simultaneously. [12] [13] [14] [15] [16] In recent years, multidrug resistance-linked transporters have gained considerable attention as potential targets to improve cancer chemotherapy and to increase bioavailability/tissue penetration of drugs. Therefore, the interaction of these transporters with targeted therapeutic drugs such as nilotinib at the molecular level needs further elucidation. To our knowledge, this is the first report that provides an understanding of the interaction of nilotinib with human P-gp through molecular modeling, mutational mapping and SAR studies. We identified residues that are crucial for binding of nilotinib to the primary site on P-gp and by using derivatives, we defined the molecular determinants of nilotinib for binding to P-gp. We believe these findings will help to synthesize novel TKIs that do not interact with P-gp, thus minimizing the possibility of development of resistance in cancer cells.
EDITOR'S NOTE
This report is important to identify the primary binding site of nilotinib in the drug-binding pocket of P-gp. It is promising in view of exploiting the designing of novel tyrosine kinase inhibitors that will not be recognised by ABC drug transporters. Figure S2 ).
